Loading...
XNAS
GBIO
Market cap35mUSD
Dec 05, Last price  
5.33USD
1D
2.11%
1Q
-11.02%
IPO
-76.70%
Name

Generation Bio Co

Chart & Performance

D1W1MN
XNAS:GBIO chart
P/E
P/S
1.81
EPS
Div Yield, %
Shrs. gr., 5y
-32.12%
Rev. gr., 5y
177.31%
Revenues
20m
+236.92%
36,00000005,904,00019,892,000
Net income
-132m
L+3.99%
-35,803,000-60,332,000-76,500,000-114,669,000-132,096,000-126,612,000-131,668,000
CFO
-89m
L+67.91%
-28,119,000-40,346,000-70,142,000-91,821,000-102,448,000-52,745,000-88,563,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Generation Bio Co., a genetic medicines company, develops therapies for the treatment of rare and prevalent diseases. The company provides a portfolio of programs, including programs for rare and prevalent diseases of the liver and retina. It also focuses on the diseases of skeletal muscle, central nervous system, and oncology. The company was formerly known as Torus Therapeutics, Inc. and changed its name to Generation Bio Co. in November 2017. Generation Bio Co. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.
IPO date
Jun 12, 2020
Employees
150
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT